AdventHealth and N-Power Forge Alliance to Reshape Cancer Research

REDWOOD CITY, CA – January 08, 2026 – A landmark collaboration between the national health system AdventHealth and oncology technology firm N-Power Medicine is set to fundamentally alter the landscape of cancer research by embedding clinical trials directly into routine community care. The strategic partnership, announced this month, will integrate N-Power’s innovative Kaleido™ Registry and Prospective External Control Arm (ProECA) platform across select AdventHealth cancer care sites in Florida, Georgia, Colorado, and Kansas.

This initiative aims to dismantle long-standing barriers that have separated advanced clinical research from the local clinics where most patients receive treatment. By bringing trial opportunities closer to home, the collaboration seeks to accelerate the development of new cancer therapies while dramatically expanding access for patients, particularly those in rural and underserved communities.

Bridging the Gap Between Care and Research

For decades, participation in a clinical trial has often meant significant travel, time, and expense for cancer patients, forcing them to choose between accessing cutting-edge treatments and staying close to their support systems. This new model aims to erase that difficult choice by integrating the mechanisms of a clinical trial into the standard workflow of a community oncology practice.

AdventHealth, a faith-based system focused on whole-person care, operates an extensive research infrastructure supporting over 800 active clinical studies. Its cancer institute is already one of Florida's most active research hubs, with more than 175 trials annually. This partnership leverages that foundation to push research beyond major academic centers.

“Access to high-quality clinical care is an important part of helping people feel whole during some of the most difficult moments of their lives,” said Dr. Michael Cacciatore, Chief Clinical Officer of AdventHealth, in a statement. “This collaboration allows us to expand access to research opportunities, especially in community and rural settings, so patients can benefit from the latest advances in cancer care close to home.”

By weaving data collection and research protocols into the fabric of everyday patient visits, the initiative promises to reduce the burden on patients and make trial participation a more feasible option for a much broader and more diverse population. This approach directly aligns with a growing industry-wide push for greater health equity in clinical research.

A New Engine for Drug Development

At the heart of the collaboration is N-Power Medicine’s sophisticated technology platform, designed to challenge the traditional, often slow-moving model of drug development. The core component, the Kaleido™ Registry, is an AI-enabled data engine that prospectively collects “trial-grade data” from consented patients during their routine care.

This system powers the Prospective External Control Arm (ProECA), a modern alternative to the conventional randomized controlled trial (RCT). In a traditional RCT, some patients receive the investigational drug while others are assigned to a control group receiving a placebo or standard of care. The ProECA model instead generates a high-quality control group from real-world data collected concurrently, mirroring the scientific rigor of a trial with defined eligibility criteria, standardized imaging schedules, and timed biomarker testing.

“Our goal is to minimize the operational divide that has traditionally separated clinical care from clinical research,” explained Dr. Michael Seiden, Chief Medical Officer of N-Power Medicine. “By providing both cutting-edge technology and a team of dedicated research professionals to AdventHealth, we enable community oncologists to actively participate in research and bring more therapies to patients faster.”

This model promises significant efficiency gains. N-Power suggests its approach can reduce patient enrollment requirements by up to 50% and shorten trial timelines by 6 to 12 months, potentially saving tens of millions of dollars per development program. This acceleration is critical in oncology, where delays can directly impact patient survival.

Strategic Integration in a Shifting Landscape

The partnership represents more than just a technological upgrade; it is a strategic move that positions AdventHealth at the forefront of a major industry transformation. The oncology research field is rapidly moving toward decentralized clinical trials (DCTs), a trend supercharged by the COVID-19 pandemic. Major clinical trial solution providers like Medidata and IQVIA are also heavily invested in AI-powered platforms and real-world data integration to streamline studies.

By adopting N-Power’s platform, AdventHealth not only enhances its already formidable research capabilities but also creates a more attractive network for pharmaceutical sponsors seeking to run faster, more efficient, and more inclusive trials. This strategic advantage strengthens its reputation as a leading center for cancer care and innovation, aligning with its mission to provide holistic, state-of-the-art care.

The industry's shift is underpinned by growing regulatory acceptance. The U.S. Food and Drug Administration (FDA) has increasingly signaled its support for modernizing clinical evidence generation, issuing guidance on the use of real-world data and remote trial components. Studies have already demonstrated that data gathered through decentralized methods can meet the rigorous standards required for drug approval, validating the approach N-Power and AdventHealth are now scaling.

Navigating the Road Ahead: Promise and Practicalities

While the promise of this integrated model is immense, its successful implementation will require navigating several practical and ethical challenges. For patients, the shift involves adapting to new technologies for remote monitoring and data sharing, which may present a hurdle for those with limited digital literacy. Furthermore, the collection of vast amounts of sensitive health data necessitates unimpeachable data privacy and security frameworks to maintain patient trust.

For providers and health systems, the integration demands significant operational adjustments. Clinical staff will require training on new workflows and technologies, and institutional policies must be adapted to support the hybrid care-research model. Ensuring seamless communication between local oncology teams, research coordinators, and technology platforms will be critical to maintaining patient safety and data integrity.

Ethical oversight from Institutional Review Boards (IRBs) will be paramount in this new paradigm, particularly concerning the processes for informed consent. Ensuring patients fully comprehend how their data will be used in a decentralized environment is a key responsibility. Despite these hurdles, the collaboration between N-Power Medicine and AdventHealth marks a pivotal step toward a more connected, patient-centered, and efficient future for oncology research. The success of this initiative could ultimately serve as a blueprint for how healthcare systems nationwide integrate the next generation of clinical research into the fabric of everyday patient care.